elōs Technology

Electro-Optical Synergy (ELOS) is a selective photothermolysis technology developed by the corporation Israel's Syneron Medical Ltd, that uses various forms of radio and light frequencies principally for cosmetic medicial purposes.

Syneron has recently presented its new line of skin ablation fractional devices that include the Matrix RF applicator for Syneron's eLight, eLaser and eMax at the 66th Annual Meeting of the American Academy of Dermatology.

The company has also presented a device that has received clearance from the U.S. Food and Drug Administration for laser-assisted lipolysis and features disposable fiber optics.

In addition to these two new devices, Syneron has also presented its VelaShape™ device, the first FDA-cleared Class II device for the temporary reduction of the appearance of cellulite that delivers non-invasive cellulite and circumferential reduction treatments.

All devices are powered by proprietary elōs™ Technology, and deliver Bi-Polar Radio Frequency and Light energies that allows the devices to treat a wide range of conditions, such as Hair Removal, Wrinkle Reduction, Vascular Advanced or Fractional Skin Treatment, while minimizing the applied light energy and its long list of associated undesired side effects.

elōs™ Technology was developed by IPL inventor/patent-holder Dr. Shimon Eckhouse and master physicist, Dr. Michael Kreindel.

This revolutionary technology platform effectively overcomes the safety and procedural limitations of intense pulse light (IPL) and conventional lasers.

Clinical Applications

• Delivers treatment to the deep dermal levels to allow for new collagen generation, while protecting the epidermis
• Selective heating within matrix thermal bands allows surrounding tissue to remain undamaged, promoting quicker healing time and minimizes the downtime
• Light and RF energies reduce sebaceous gland activity while blue light destroys acne
• Treat even minimally-pigmented hair colors and all skin colors
• Treat superficial benign vascular and pigmented lesions including Telangiectasias, Rosacea, Poikiloderma and Angioma. FotoFacialRF.
• Resolve vascular lesions in 1-3 treatments
• Selective thermolysis to vascular lesions and leg veins up to 4-mm
• Can also be applied on advanced vascular and smaller resistant vessels including fine telangiectasias
  

More Info:
Syneron

Source:
Medical Gadget Inspector